{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,24]],"date-time":"2026-01-24T18:54:54Z","timestamp":1769280894275,"version":"3.49.0"},"reference-count":21,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2011,9,1]],"date-time":"2011-09-01T00:00:00Z","timestamp":1314835200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2011,9,1]],"date-time":"2011-09-01T00:00:00Z","timestamp":1314835200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,6,8]],"date-time":"2022-06-08T00:00:00Z","timestamp":1654646400000},"content-version":"vor","delay-in-days":3933,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","exphem.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Experimental Hematology"],"published-print":{"date-parts":[[2011,9]]},"DOI":"10.1016\/j.exphem.2011.06.005","type":"journal-article","created":{"date-parts":[[2011,6,26]],"date-time":"2011-06-26T12:14:15Z","timestamp":1309090455000},"page":"897-903.e1","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"title":["Clinical scale expansion of cytokine-induced killer cells is feasible from healthy donors and patients with acute and chronic myeloid leukemia at various stages of therapy"],"prefix":"10.1016","volume":"39","author":[{"given":"Madelaine","family":"Niam","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yeh-Ching","family":"Linn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephanie","family":"Fook Chong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tsyr-Jong","family":"Lim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sixian","family":"Chu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alicia","family":"Choong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hao-Xiang","family":"Yong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Garnet","family":"Suck","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marieta","family":"Chan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mickey","family":"Koh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.exphem.2011.06.005_bib1","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.4049\/jimmunol.153.4.1687","article-title":"A novel population of expanded human CD3+CD56+ cells derived from T cells with potent in\u00a0vivo antitumor activity in mice with severe combined immunodeficiency","volume":"153","author":"Lu","year":"1994","journal-title":"J Immunol"},{"key":"10.1016\/j.exphem.2011.06.005_bib2","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1084\/jem.174.1.139","article-title":"Use of a SCID mouse\/human lymphoma model to evaluate cytokine-induced killer cells with potent antitumor cell activity","volume":"174","author":"Schmidt-Wolf","year":"1991","journal-title":"J Exp Med"},{"key":"10.1016\/j.exphem.2011.06.005_bib3","doi-asserted-by":"crossref","first-page":"3318","DOI":"10.1182\/blood.V92.9.3318","article-title":"Expansion of Philadelphia chromosome-negative CD3(+)CD56(+) cytotoxic cells from chronic myeloid leukemia patients: in\u00a0vitro and in\u00a0vivo efficacy in severe combined immunodeficiency disease mice","volume":"92","author":"Hoyle","year":"1998","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2011.06.005_bib4","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1046\/j.1365-2141.2002.03247.x","article-title":"Generation of cytokine-induced killer cells from leukaemic samples with in\u00a0vitro cytotoxicity against autologous and allogeneic leukaemic blasts","volume":"116","author":"Linn","year":"2002","journal-title":"Br J Haematol"},{"key":"10.1016\/j.exphem.2011.06.005_bib5","first-page":"580","article-title":"Autologous cytokine-induced killer cells as post-transplant cellular immunotherapy","volume":"110","author":"Arai","year":"2007","journal-title":"ASH Annual Meeting Abstracts"},{"key":"10.1016\/j.exphem.2011.06.005_bib6","first-page":"412","article-title":"Cytokine induced killer (CIK) cells as post-transplant immunotherapy following allogeneic hematopoietic cell transplantation","volume":"108","author":"Laport","year":"2006","journal-title":"ASH Annual Meeting Abstracts"},{"key":"10.1016\/j.exphem.2011.06.005_bib7","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.bbmt.2004.11.019","article-title":"A phase I trial of autologous cytokine-induced killer cells for the treatment of relapsed Hodgkin disease and non-Hodgkin lymphoma","volume":"11","author":"Leemhuis","year":"2005","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.exphem.2011.06.005_bib8","doi-asserted-by":"crossref","first-page":"952","DOI":"10.3324\/haematol.11132","article-title":"Repeated infusions of donor-derived cytokine-induced killer cells in patients relapsing after allogeneic stem cell transplantation: a phase I study","volume":"92","author":"Introna","year":"2007","journal-title":"Haematologica"},{"key":"10.1016\/j.exphem.2011.06.005_bib9","first-page":"198","article-title":"[The efficacy of chemotherapy in combination with auto-cytokine-induced killer cells in acute leukemia]","volume":"44","author":"Jiang","year":"2005","journal-title":"Zhonghua Nei Ke Za Zhi"},{"key":"10.1016\/j.exphem.2011.06.005_bib10","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1053\/bbmt.2001.v7.pm11349808","article-title":"Expansion of cytotoxic CD3+ CD56+ cells from peripheral blood progenitor cells of patients undergoing autologous hematopoietic cell transplantation","volume":"7","author":"Alvarnas","year":"2001","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.exphem.2011.06.005_bib11","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1111\/j.1365-2567.2008.02910.x","article-title":"Characterization of the recognition and functional heterogeneity exhibited by cytokine-induced killer cell subsets against acute myeloid leukaemia target cell","volume":"126","author":"Linn","year":"2009","journal-title":"Immunology"},{"key":"10.1016\/j.exphem.2011.06.005_bib12","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1007\/s002620000148","article-title":"CD58\/LFA-3 and IL-12 provided by activated monocytes are critical in the in\u00a0vitro expansion of CD56+ T cells","volume":"49","author":"Lopez","year":"2001","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.exphem.2011.06.005_bib13","first-page":"1673","article-title":"Phenotypic characterization and identification of effector cells involved in tumor cell recognition of cytokine-induced killer cells","volume":"21","author":"Schmidt-Wolf","year":"1993","journal-title":"Exp Hematol"},{"key":"10.1016\/j.exphem.2011.06.005_bib14","doi-asserted-by":"crossref","first-page":"234540","DOI":"10.1155\/2010\/234540","article-title":"Exploration of the lysis mechanisms of leukaemic blasts by chimaeric T-cells","volume":"2010","author":"Laurin","year":"2010","journal-title":"J Biomed Biotechnol"},{"key":"10.1016\/j.exphem.2011.06.005_bib15","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1182\/blood-2010-06-290858","article-title":"Enhanced killing of human B-cell lymphoma targets by combined use of cytokine-induced killer cell (CIK) cultures and anti-CD20 antibodies","volume":"117","author":"Pievani","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2011.06.005_bib16","doi-asserted-by":"crossref","first-page":"3909","DOI":"10.1182\/blood-2009-02-206946","article-title":"Peripheral blood T cells in acute myeloid leukemia (AML) patients at diagnosis have abnormal phenotype and genotype and form defective immune synapses with AML blasts","volume":"114","author":"Le","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2011.06.005_bib17","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1007\/s00262-004-0505-0","article-title":"Functional characterization of T\u00a0lymphocytes derived from patients with acute myelogenous leukemia and chemotherapy-induced leukopenia","volume":"53","author":"Wendelbo","year":"2004","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.exphem.2011.06.005_bib18","doi-asserted-by":"crossref","first-page":"4422","DOI":"10.1182\/blood.V86.12.4422.bloodjournal86124422","article-title":"Pretreatment of donor mice with granulocyte colony-stimulating factor polarizes donor T lymphocytes toward type-2 cytokine production and reduces severity of experimental graft-versus-host disease","volume":"86","author":"Pan","year":"1995","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2011.06.005_bib19","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1182\/blood.V92.1.215.413k10_215_222","article-title":"Production of interleukin-10 by granulocyte colony-stimulating factor-mobilized blood products: a mechanism for monocyte-mediated suppression of T-cell proliferation","volume":"92","author":"Mielcarek","year":"1998","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2011.06.005_bib20","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1126\/science.1178334","article-title":"Mechanisms underlying lineage commitment and plasticity of helper CD4+ T cells","volume":"327","author":"O\u2019Shea","year":"2010","journal-title":"Science"},{"key":"10.1016\/j.exphem.2011.06.005_bib21","doi-asserted-by":"crossref","first-page":"2473","DOI":"10.1182\/blood-2004-07-2527","article-title":"Imatinib inhibits T-cell receptor-mediated T-cell proliferation and activation in a dose-dependent manner","volume":"105","author":"Seggewiss","year":"2005","journal-title":"Blood"}],"container-title":["Experimental Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0301472X11002839?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0301472X11002839?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T08:29:11Z","timestamp":1759566551000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0301472X11002839"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,9]]},"references-count":21,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2011,9]]}},"alternative-id":["S0301472X11002839"],"URL":"https:\/\/doi.org\/10.1016\/j.exphem.2011.06.005","relation":{},"ISSN":["0301-472X"],"issn-type":[{"value":"0301-472X","type":"print"}],"subject":[],"published":{"date-parts":[[2011,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical scale expansion of cytokine-induced killer cells is feasible from healthy donors and patients with acute and chronic myeloid leukemia at various stages of therapy","name":"articletitle","label":"Article Title"},{"value":"Experimental Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.exphem.2011.06.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2011 ISEH - Society for Hematology and Stem Cells. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}